Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Exclusion Criteria

• •1. Subject has exclusively constipation-predominant IBS (CIBS) that is characterized by \< 3 bowel movements/week or hard and lumpy stools.
• •2. Subject has alternating IBS, but is currently presenting with constipation associated IBS symptoms.
• •3. Subject has had adequate control of their DIBS and their symptom of bloating the week preceding the screening visit or at the time of randomization. Bloating includes the following symptoms: abdominal fullness, bloating, gas, or swelling.
• •4. Subjects has a positive stool culture for O \& P (ovum and parasite) and/or Clostridium difficile
• •5. Subject has failed to record 2 negative weekly global assessments during the past 10 days prior to randomization.